17 Februari 2012
ACAB is specialized in advanced radar dome technology (photo : Volvo Aero)
The Volvo Aero owned company, Applied Composites AB – ACAB – has been appointed by LIG Nex1, a LIG Group company in South Korea, for the development of a prototype stealth radome for the KFX aircraft programme.
ACAB is recognized as one of the leading European suppliers of advanced composite components for military applications. Among other things, ACAB is specialized in advanced radome technology, including the latest generation stealth and low-observable technology. ACAB has supported and supplied Saab for over half a century with radome technology for the Saab fighter programmes. ACAB is the supplier of the Gripen fighter radomes.
LIG Nex1 is South Korea’s number one company on military products. LIG Nex1 is working in close collaboration with advanced global companies. LIG Nex1 is developing state-of-the-art weapon systems, including radar and surveillance systems.
The radome (radar dome) is the streamlined structural part in the nose of the aircraft which protects the radar antenna from wind and weather. It is carefully designed to withstand the mechanical loads without compromising the radar performance. In addition, it increases the survivability of the aircraft due to its sophisticated stealth features.
The KFX aircraft is intended to replace South Korea’s aging F-4 Phantom II and F-5 Tiger II aircraft. The production numbers are estimated to exceed 250 aircraft. The contract includes exploratory development and production of prototypes for an undisclosed contract value. It is still too early to determine the number of people at ACAB that will be involved in development and production.
“We are very proud of and pleased with the contract from LIG Nex1 since it consolidates our position as world leader in radomes” says Torgny Stenholm, President of ACAB.
“In addition, the agreement is considered to be strategically important for ACAB as the company has plans to expand within the commercial and military aerospace segments”, he adds.
No comments:
Post a Comment